Live feed02:30:00·50dPRReleasevia QuantisnowENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast CancerByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
